NASDAQ:LUCD Lucid Diagnostics (LUCD) Stock Price, News & Analysis $0.98 -0.01 (-0.92%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$0.98 0.00 (-0.29%) As of 08/7/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lucid Diagnostics Stock (NASDAQ:LUCD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lucid Diagnostics alerts:Sign Up Key Stats Today's Range$0.95▼$1.0250-Day Range$0.98▼$1.5252-Week Range$0.73▼$1.80Volume521,660 shsAverage Volume927,868 shsMarket Capitalization$106.11 millionP/E RatioN/ADividend YieldN/APrice Target$3.55Consensus RatingBuy Company Overview Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc. Read More Lucid Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreLUCD MarketRank™: Lucid Diagnostics scored higher than 55% of companies evaluated by MarketBeat, and ranked 449th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingLucid Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLucid Diagnostics has only been the subject of 3 research reports in the past 90 days.Read more about Lucid Diagnostics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lucid Diagnostics are expected to grow in the coming year, from ($0.84) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lucid Diagnostics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lucid Diagnostics is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Lucid Diagnostics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.87% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lucid Diagnostics has recently decreased by 1.24%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLucid Diagnostics does not currently pay a dividend.Dividend GrowthLucid Diagnostics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.87% of the float of Lucid Diagnostics has been sold short.Short Interest Ratio / Days to CoverLucid Diagnostics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lucid Diagnostics has recently decreased by 1.24%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.33 News SentimentLucid Diagnostics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lucid Diagnostics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for LUCD on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Lucid Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lucid Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.80% of the stock of Lucid Diagnostics is held by insiders.Percentage Held by Institutions74.01% of the stock of Lucid Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lucid Diagnostics' insider trading history. Receive LUCD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucid Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address LUCD Stock News HeadlinesLucid Diagnostics to Participate in Upcoming Investor ConferencesAugust 5 at 8:00 AM | prnewswire.comLucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Rating of "Buy" from BrokeragesAugust 5 at 2:11 AM | americanbankingnews.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. | Brownstone Research (Ad)PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025July 31, 2025 | prnewswire.comPAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleJuly 30, 2025 | finance.yahoo.comLucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025July 30, 2025 | prnewswire.comLucid nearing Medicare coverage for EsoGuard test, maintain at Buy: BTIGJuly 28, 2025 | msn.comLucid says meeting scheduled to determine Medicare coverage for cancer testJuly 16, 2025 | msn.comSee More Headlines LUCD Stock Analysis - Frequently Asked Questions How have LUCD shares performed this year? Lucid Diagnostics' stock was trading at $0.8187 on January 1st, 2025. Since then, LUCD shares have increased by 19.8% and is now trading at $0.9808. How were Lucid Diagnostics' earnings last quarter? Lucid Diagnostics Inc. (NASDAQ:LUCD) released its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.26) earnings per share for the quarter. The business earned $1.04 million during the quarter. Read the conference call transcript. When did Lucid Diagnostics IPO? Lucid Diagnostics (LUCD) raised $75 million in an initial public offering (IPO) on Thursday, October 14th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Who are Lucid Diagnostics' major shareholders? Top institutional shareholders of Lucid Diagnostics include Parallel Advisors LLC (0.04%) and Traphagen Investment Advisors LLC (0.03%). View institutional ownership trends. How do I buy shares of Lucid Diagnostics? Shares of LUCD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lucid Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lucid Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Netflix (NFLX), Clean Energy Fuels (CLNE) and Baidu (BIDU). Company Calendar Last Earnings3/26/2024Today8/08/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:LUCD CIK1799011 Webwww.luciddx.com Phone212-949-4319FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Price Target for Lucid Diagnostics$3.55 High Price Target$7.75 Low Price Target$2.00 Potential Upside/Downside+261.9%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$45.53 million Net Margins-1,699.86% Pretax Margin-1,481.55% Return on EquityN/A Return on Assets-124.27% Debt Debt-to-Equity RatioN/A Current Ratio0.75 Quick Ratio0.74 Sales & Book Value Annual Sales$4.17 million Price / Sales25.43 Cash FlowN/A Price / Cash FlowN/A Book Value($0.78) per share Price / Book-1.26Miscellaneous Outstanding Shares108,189,000Free Float100,832,000Market Cap$106.11 million OptionableNo Data Beta1.21 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:LUCD) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lucid Diagnostics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lucid Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.